TRiNDS Team Spotlight: Lauren Morgenroth, TRiNDS Chief Executive Officer

June 25, 2020

TRiNDS Team Spotlight:  Lauren Morgenroth, TRiNDS Chief Executive Officer

All of us at TRiNDS come to work every day committed to conducting the best quality rare disease and neuromuscular research. Today we’d like to introduce Lauren Morgenroth, TRiNDS Chief Executive Officer. We sat down with Lauren to learn more about her and her work.

How did you come to work in clinical research?

Lauren: I began my career in clinical research in a work-study position focused on epilepsy while obtaining my Bachelor of Science at the University of Miami. This led to a full-time position running a large collaborative study for the US Department of Veterans Affairs in Miami, FL. I eventually found my calling working with CINRG – The Cooperative International Neuromuscular Research Group, an academic clinical trial network with a goal of positively impacting the lives of neuromuscular patients and their families by conducting well-controlled clinical studies. This was the perfect match for my genetic counseling background and research operation management skills.

Why was TRiNDS created?

Lauren: TRiNDS was launched in 2016 in response to unmet needs from our neuromuscular community to have a dedicated and focused contract research organization (CRO) with specific expertise in Duchenne muscular dystrophy (DMD). The landscape for clinical research was also prime as an increased number of pharmaceutical companies were entering the neuromuscular and DMD space. We wanted to bring a novel and efficient solution for managing clinical research projects.

What are you most excited about for the future of neuromuscular research?

Lauren: I am most excited to see the growing awareness of research opportunities and increased interest from pharmaceutical companies to make a difference in the lives of individuals living with neuromuscular disorders. When I choose a career in genetics and rare disease research, I was warned I may never see a real change and that I was part of a slow but important process. I have seen the change and at TRiNDS we push to reach additional patients, families and involve more sites around the world.

TRiNDS leverages experience from rare neuromuscular disease research to create the tools and systems needed for efficient clinical trial success. We understand the need for flexibility and creativity to reduce the burden of clinical trial participation while maintaining projects’ safety and overall integrity.

Contact us for more information about how TRiNDS can help your project succeed.